课题基金 / 基金详情

Development of a Bacterial Ghost DNA vaccine for Influenza using antibody epitope

Development of a Bacterial Ghost DNA vaccine for Influenza using antibody epitope
使用抗体表位开发流感细菌幽灵 DNA 疫苗
批准号:
7487472
负责人:
Vito G DelVecchio
金额:
$28.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-01 至 2010-08-31

项目摘要

项目成果

Vito G DelVecchio的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Influenza epidemics and pandemics are major threats to human health. Vaccination is the primary strategy for the control of annual and emerging influenza pandemics. Present influenza vaccine platforms and production systems are inflexible, slow, expensive, and cannot rapidly respond to an emerging strain of virus. Thus, new technologies for the rapid development and production of influenza vaccines are urgently needed. With these challenges in mind this proposal is aimed at demonstrating the feasibility of implementing a vaccine strategy combining the novel technologies of Bacterial Ghosts, DNA minicircles, and proteomics-based antibody epitope mapping. Proteomics technologies will be used to rapidly identify antibody binding epitopes in the influenza H1 protein using sera from animals exposed to H1 protein or H1 containing virus. The resulting epitopes will be used to develop and produce Bacterial Ghost vaccines with immobilized minicircle DNA constructs. Bacterial Ghosts have recently been used as carriers and stimulators of DNA minicircle vaccines with promising results. DNA minicircles eliminate many of the risks involved in vaccination with plasmid DNA and are incorporated into BG in a one-step low cost production process. Animals will undergo a scheduled vaccination scheme using the produced Bacterial Ghost vaccines and the immune response will be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a Bacterial Ghost DNA vaccine for Influenza using antibody epitope
  • 批准号:
    7328516
  • 项目类别:
  • 资助金额:
    $28.94万
  • 财政年份:
    2007
  • 负责人:
    Vito G DelVecchio
  • 依托单位:
海外基金